Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

Eupraxia Pharmaceuticals reported new trial data showing EP-104GI improved esophagus tissue health and maintained remission ...

As of Thursday, January 08, Phathom Pharmaceuticals, Inc.’s PHAT share price has dipped by 15.15%, which has investors ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete improvement in tissue health1- At lower doses, patients maintained the improvem ...

At week 12, the highest dosed patients achieved the best tissue response seen in the trial to date, with a near complete ...

Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.

We read with interest the article by Santacroce about personalised medicine in eosinophilic oesophagitis (EoE) and the ...

Apogee Therapeutics ( ($APGE) ) has provided an announcement. On January 6, 2026, Apogee Therapeutics reported positive interim results from a ...

"2025 was a year that demonstrated Bambusa's execution-first culture," said Dr. Xu. "With multiple clinical programs advancing in parallel, we are entering 2026 positioned to deliver up to 10 clinical ...

New York Army National Guard Command Sgt. Maj. Curtis L. Moss was recognized for 30 years of exemplary service.

Eosinophilic esophagitis (EoE) is no longer a rarity in European clinics. Diagnosed increasingly over the past three decades, EoE is commonly managed with pharmacotherapy, elimination diets, and, when ...